MCID: CNS004
MIFTS: 58

Constipation

Categories: Gastrointestinal diseases

Aliases & Classifications for Constipation

MalaCards integrated aliases for Constipation:

Name: Constipation 12 29 6 42 43 15 32

Classifications:



External Ids:

Disease Ontology 12 DOID:2089
ICD9CM 34 564.0
MeSH 43 D003248
NCIt 49 C37930
SNOMED-CT 67 14760008
ICD10 32 K59.0
UMLS 71 C0009806

Summaries for Constipation

MedlinePlus : 42 Constipation means that a person has three or fewer bowel movements in a week. The stool can be hard and dry. Sometimes it is painful to pass. At one time or another, almost everyone gets constipated. In most cases, it lasts a short time and is not serious. There are many things you can do to prevent constipation. They include Eating more fruits, vegetables and grains, which are high in fiber Drinking plenty of water and other liquids Getting enough exercise Taking time to have a bowel movement when you need to Using laxatives only if your doctor says you should Asking your doctor if medicines you take may cause constipation It's not important that you have a bowel movement every day. If your bowel habits change, however, check with your doctor. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Constipation is related to outlet dysfunction constipation and irritable bowel syndrome. An important gene associated with Constipation is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Hydrocodone and Ondansetron have been mentioned in the context of this disorder. Affiliated tissues include colon, breast and testes, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A bowel dysfunction that is characterized by infrequent or difficult evacuation of feces.

Wikipedia : 74 Constipation refers to bowel movements that are infrequent or hard to pass. The stool is often hard and... more...

Related Diseases for Constipation

Diseases related to Constipation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 700)
# Related Disease Score Top Affiliating Genes
1 outlet dysfunction constipation 34.7 SLC6A4 HTR3A
2 irritable bowel syndrome 33.9 VIP TAC1 SST SLC6A4 PYY OPRM1
3 hirschsprung disease 1 33.7 VIP TAC1 RET KIT GDNF CALCA
4 intestinal obstruction 33.3 SST RET MLN KIT GDNF FLNA
5 hypoganglionosis 33.2 RET GDNF
6 neurogenic bowel 33.2 VIP MLN
7 eating disorder 33.1 SLC6A4 PYY OPRM1 CCK
8 central hypoventilation syndrome, congenital 32.8 TAC1 RET GDNF
9 diarrhea 32.5 TAC1 SST SLC6A4 PYY OPRM1 MLN
10 megacolon 32.2 VIP RET KIT GDNF
11 ileus 32.0 VIP SST OPRM1 MLN CCK CALCA
12 anismus 31.9 VIP CLCN2
13 gastroesophageal reflux 31.7 VIP PYY MLN CCK
14 pain agnosia 31.6 TAC1 OPRM1 HTR3A CCK CALCA
15 gastroparesis 31.5 SST MLN HTR3A CCK
16 achalasia 31.5 VIP RET KIT GDNF
17 paralytic ileus 31.5 VIP TAC1 OPRM1 MLN HTR3A
18 hydrocephalus 31.4 VIP SST GDNF FLNA
19 anxiety 31.4 TAC1 SLC6A4 OPRM1 HTR3A CCK
20 colonic pseudo-obstruction 31.4 SST MLN HTR4
21 functional diarrhea 31.4 HTR3A CLCN2
22 carcinoid syndrome 31.3 SST PYY HTR3A CALCA
23 vesicoureteral reflux 1 31.3 RET GDNF EBF3
24 multiple endocrine neoplasia 31.3 RET GDNF CALCA
25 headache 31.2 TAC1 CCK CALCA
26 migraine with or without aura 1 31.2 VIP TAC1 SLC6A4 PPOX OPRM1 HTR3A
27 gastroenteritis 31.1 PYY MLN CALCA
28 autism 31.1 TAC1 SLC6A4 OPRM1 HTR3A GDNF CCK
29 fibromyalgia 31.0 SLC6A4 OPRM1 HTR3A CALCA
30 rare tumor 31.0 SST RET KIT
31 pheochromocytoma 31.0 VIP SST RET MLN KIT GDNF
32 ganglioneuroma 31.0 VIP SST RET
33 multiple endocrine neoplasia, type iib 31.0 RET GDNF CALCA
34 duodenal ulcer 31.0 SST MLN CCK CALCA
35 somatoform disorder 30.9 TAC1 SLC6A4 OPRM1 HTR3A CALCA
36 obsessive-compulsive disorder 30.9 SST SLC6A4 HTR3A CCK
37 neuroblastoma 30.9 VIP SST RET OPRM1 KIT GDNF
38 psychotic disorder 30.9 SLC6A4 OPRM1 HTR3A CCK
39 peripheral nervous system disease 30.9 TAC1 OPRM1 GDNF CALCA
40 drug dependence 30.9 SLC6A4 OPRM1 HTR3A
41 neuroma 30.8 RET KIT GDNF CALCA
42 dumping syndrome 30.8 SST PYY MLN CCK
43 schizophrenia 30.8 SST SLC6A4 OPRM1 HTR4 HTR3A GDNF
44 somatization disorder 30.8 TAC1 SLC6A4 FLNA
45 serotonin syndrome 30.8 TAC1 SST SLC6A4 PYY HTR3A
46 gallbladder disease 30.8 SST PYY MLN CCK
47 paraganglioma 30.7 SST RET KIT CALCA
48 paine syndrome 30.7 TAC1 OPRM1 HTR3A CALCA
49 stomach disease 30.7 SST MLN CCK
50 functional colonic disease 30.7 SST MLN

Graphical network of the top 20 diseases related to Constipation:



Diseases related to Constipation

Symptoms & Phenotypes for Constipation

GenomeRNAi Phenotypes related to Constipation according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00249-S 9.36 MLN SLC6A4
2 Decreased viability GR00381-A-1 9.36 HTR3A MLN SLC6A4
3 Decreased viability GR00381-A-3 9.36 HTR3A MLN SLC6A4
4 Decreased viability GR00386-A-1 9.36 MLN
5 Decreased viability GR00402-S-2 9.36 HTR3A MLN

MGI Mouse Phenotypes related to Constipation:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.28 CLCN2 FLNA GDNF HTR3A HTR4 KIT
2 homeostasis/metabolism MP:0005376 10.13 CCK CLCN2 FLNA HTR3A HTR4 KIT
3 mortality/aging MP:0010768 10.07 EBF3 FLNA GDNF HTR3A HTR4 KIT
4 digestive/alimentary MP:0005381 10.06 CLCN2 FLNA GDNF KIT OPRM1 PPOX
5 endocrine/exocrine gland MP:0005379 10.02 CCK CLCN2 GDNF HTR3A KIT OPRM1
6 nervous system MP:0003631 10 CCK CLCN2 EBF3 FLNA GDNF HTR3A
7 normal MP:0002873 9.61 FLNA KIT OPRM1 PYY RET SLC6A4
8 renal/urinary system MP:0005367 9.17 CCK GDNF HTR3A KIT PPOX RET

Drugs & Therapeutics for Constipation

Drugs for Constipation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 637)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
2
Ondansetron Approved Phase 4 99614-02-5 4595
3
Cyclobenzaprine Approved Phase 4 303-53-7 2895
4
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
5
Lornoxicam Approved, Investigational Phase 4 70374-39-9 5282204
6
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
7
Orphenadrine Approved Phase 4 83-98-7 4601
8
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
9
Morphine Approved, Investigational Phase 4 57-27-2 5288826
10
Simethicone Approved Phase 4 8050-81-5
11
Sorbitol Approved Phase 4 50-70-4 5780
12
Methadone Approved Phase 4 76-99-3 4095
13
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
14
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
15
Alverine Approved, Investigational Phase 4 150-59-4 3678
16
Mebeverine Approved, Investigational Phase 4 3625-06-7 62887
17
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
18
Calcium carbonate Approved, Investigational Phase 4 471-34-1
19
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
20
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 54677470 5281106
21
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
22
Turmeric Approved, Experimental, Investigational Phase 4
23
Coal tar Approved Phase 4 8007-45-2
24
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
25
Metronidazole Approved Phase 4 443-48-1 4173
26
Desflurane Approved Phase 4 57041-67-5 42113
27
Topiramate Approved Phase 4 97240-79-4 5284627
28
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
29 Apricot Approved Phase 4
30
Gliclazide Approved Phase 4 21187-98-4 3475
31
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
32
Metformin Approved Phase 4 657-24-9 14219 4091
33
dihydrocodeine Approved, Illicit Phase 4 125-28-0 5284543
34
Labetalol Approved Phase 4 36894-69-6 3869
35
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
36
Propranolol Approved, Investigational Phase 4 525-66-6 4946
37
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
38
Ferrous succinate Approved Phase 4 10030-90-7
39
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
40
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
41
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
42
Nitrofurantoin Approved, Vet_approved Phase 4 67-20-9 5353830
43
Chlorzoxazone Approved Phase 4 95-25-0 2733
44
Palonosetron Approved, Investigational Phase 4 135729-56-5, 119904-90-4 148211
45
4-Aminopyridine Approved Phase 4 504-24-5 1727
46
Lactulose Approved Phase 4 4618-18-2 11333
47
Sodium citrate Approved, Investigational Phase 4 68-04-2
48
tannic acid Approved Phase 4 1401-55-4
49
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
50
Mineral oil Approved, Vet_approved Phase 4 8042-47-5

Interventional clinical trials:

(show top 50) (show all 1618)
# Name Status NCT ID Phase Drugs
1 Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects Unknown status NCT02433847 Phase 4 Mosapride
2 Comparative Study Between Botulinum Toxin Injection and Myectomy in Treatment of Idiopathic Constipation in Children Unknown status NCT02361749 Phase 4 Botulinum Toxin
3 Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section Unknown status NCT02571881 Phase 4 Oxycodone;oxycodone-naloxone
4 Polyethylene Glycol for Childhood Constipation Unknown status NCT01875744 Phase 4 Polyethylene glycol 4000
5 The Assessment of Lactobacillus Reuteri Efficacy, Provided With Forlax, as Treatment of Incurable Constipation in Children 3-7 Years. Double Blind, Placebo-controlled, Randomized and Multicenter Trial Unknown status NCT01388712 Phase 4
6 An Evaluation of the Efficacy and Safety of a Polyethylene Glycol (PEG) Based Bowel Protocol for the Management of Constipation in Peritoneal Dialysis Patients: A Pilot Study Unknown status NCT03148002 Phase 4 Current Bowel Protocol (senna/lactulose);PEG Bowel Protocol (PEG/lactulose)
7 Comparing a Probiotic and Non-probiotic Intervention in Their Ability to Improve Bowel Habits of Residents in Nursing Homes Unknown status NCT02949882 Phase 4
8 The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome- a Double Blind, Placebo - Controlled, Randomized Study Unknown status NCT01779765 Phase 4
9 Randomized, Double-Blind, Placebo-Controlled Trial of Alvimopan in Major Spine Surgery Unknown status NCT02789111 Phase 4 Alvimopan;Placebo
10 Randomized Controlled Trial Comparing the Efficacy of Polyethylene Glycol Alone and Polyethylene Glycol Combined With Topical Diltiazem in Treating Anal fissure in Children Unknown status NCT02419534 Phase 4 Polyethylene glycol;Polyethylene glycol with Diltiazem
11 Multicenter Study Evaluating the Efficacy of Dicopeg Junior in Comparison With Lactulose for the Treatment of Functional Constipation in Children Aged 6 Months to 6 Years. A Prospective, Randomized Study. Unknown status NCT03177434 Phase 4 polyethylene glycols (PEG) 3350;Lactulose Oral Product
12 The Clinical Use of Probiotics in the Uremia Patients Under Chronic Peritoneal Dialysis Unknown status NCT01076426 Phase 4 Pro-biotics
13 A Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trials to Evaluate the Efficacy and Safety of Runzao Zhiyang Capsule in Treating Chronic Eczema Unknown status NCT02601222 Phase 4 Runzao zhiyang capsule;Runzaozhiyang capsule agent simulation;Urea cream
14 Efficacy of Prucalopride Plus Polyethylene Glycol in Bowel Preparation for Colonoscopy Unknown status NCT02781493 Phase 4 2 mg Prucalopride plus 2 L Polyethylene Glycol regimen;2 mg Placebo plus 2 L Polyethylene Glycol regimen
15 A Prospective, Randomized Controlled Trial Comparing the Efficacy and Patient Tolerability of MiraLAX (PEG 3350) vs Golytely as Bowel Preparation for Screening Colonoscopy Unknown status NCT00889655 Phase 4 Golytely (polyethylene glycol);MiraLax (polyethylene glycol 3350)
16 Changes of Heart Rate Variability in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine Unknown status NCT01047215 Phase 4 Aripiprazole; Quetiapine
17 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Comparison Clinical Study to Investigate the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron With Overactive Bladder Symptoms in Men Unknown status NCT02361502 Phase 4 mirabegron;placebo
18 Role Of Saccharomyces Boulardii In Diarrhea Dominant Irritable Bowel Syndrome Unknown status NCT00543478 Phase 4 Saccharomyces boulardii;Methyl cellulose powder (low viscosity)
19 Probiotics After Discharge (PAD) Study: Impact on Microbiome, Health and Growth Outcomes Unknown status NCT02695784 Phase 4
20 Ureteral Stent-related Pain and Mirabegron (SPAM) Trial Unknown status NCT02095665 Phase 4 Mirabegron;Tamsulosin;Tylenol #3
21 EFFICACY AND SAFETY OF COMBINATION THERAPY WITH β3-ADRENOCEPTOR AGONIST (MIRABEGRON) AND α-ADRENOCEPTOR ANTAGONIST (TAMSULOSIN) FOR TREATMENT OF OVERACTIVE BLADDER IN MALE PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. Unknown status NCT02279615 Phase 4 Mirabegron;Tamsulosin
22 A Study of the Utility of Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease Double Blind Placebo Control Crossover Pilot Study Unknown status NCT02472210 Phase 4 Botulinum Toxin
23 Prucalopride Versus Placebo in Functional Dyspepsia With Delayed Gastric Emptying Unknown status NCT02510976 Phase 4 prucalopride;placebo
24 Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome Unknown status NCT01312259 Phase 4
25 Solifenacin vs Levofloxacin vs Lornoxicam for Management of Intravesical Instillation of Bacillus Calmette-Guerin (BCG) Side Effects A Single Blinded Randomised Controlled Study Unknown status NCT03038321 Phase 4 sofenacin;Tavanic;Xefo
26 Randomized Placebo Controlled Trial of Postoperative Pain After Intravenous Vitamin C Injection for Arthroscopic Rotator Cuff Repair Unknown status NCT02992028 Phase 4 Intravenous Nutrition (Vitamins) injection;Intravenous Saline injection
27 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
28 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
29 Evaluation of the Efficacy of Exparel Delivered Into the Hip Capsule During Hemiarthroplasty Unknown status NCT03502018 Phase 4 Bupivacaine liposome;Saline
30 An Eight Week, Double-Blind Efficacy Study of Cyclobenzaprine ER (Amrix TM) Augmentation to Alleviate Fibromyalgia Fatigue and Muscle Pain Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
31 Bilateral Transversus Abdominis Plane Block With or Without Magnesium for Total Abdominal Hysterectomy With or Without Salpingo-oophorectomy: a Randomized Controlled Trial Unknown status NCT02680626 Phase 4 Magnesium Sulfate;Ropivacaine
32 Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery as Part of an Enhanced Recovery After Surgery Protocol: A Randomized Prospective Single- Center Trial. Unknown status NCT02958566 Phase 4 Acetaminophen;Gabapentin;Orphenadrine;Lidocaine;Marcaine;Ketamine;Methadone;Tramadol;Ketorolac;Morphine Sulfate;Fentanyl;Dilaudid;Hydrocodone-Acetaminophen Tab 5-325 MG;Morphine Sulfate;Fentanyl;Dilaudid;HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
33 Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
34 Comparative Study of Antiemetic Effect of Ramosetron With Combination of Ondansetron and Dexamethasone in Patients Undergoing Laparoscopic Cholecystectomy Unknown status NCT02803788 Phase 4 ramosetron, ondansetron, dexamethasone
35 Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone Unknown status NCT00480844 Phase 4 Sertindole;Risperidone
36 The ACT-OUT Trial: ACTivity OUTcomes Based on the Consumption of a High Carbohydrate or High Fat Diet in Patients With Metabolic Syndrome Unknown status NCT01357382 Phase 4
37 Sacral Nerve Stimulation for Anal Incontinence and Bowel Control Completed NCT00200005 Phase 4
38 PolyethyleneGlycol3350 Laxative vs Placebo in Constipated Children Completed NCT00153114 Phase 4 polyethyleneglycol3350
39 Opioid Induced Bowel Dysfunction in Patients Undergoing Spinal Surgery Completed NCT02573922 Phase 4 oxycodone-naloxone;Oxycodone
40 A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation Completed NCT00171522 Phase 4 Tegaserod and Polyethylene Glycol 3350
41 Polyethyleneglycol3350 vs Tegaserod in Treatment of Patients With Chronic Constipation Completed NCT00153140 Phase 4 polyethyleneglycol3350
42 A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children Completed NCT00319670 Phase 4 MiraLax
43 Effects of Lubiprostone on Gastric Sensory and Motor Function in Patients With Chronic Idiopathic Constipation Completed NCT01460225 Phase 4 lubiprostone
44 Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications Completed NCT01096290 Phase 4 lubiprostone;Matched placebo
45 A Randomized, Double-Blind, Placebo-Controlled Study Of A Fixed Dose Of Subcutaneous Methylnaltrexone In Adults With Advanced Illness And Opioid-Induced Constipation: Efficacy, Safety, And Additional Health Outcomes Completed NCT00672477 Phase 4 Methylnaltrexone;Placebo
46 An Open Label Study of Chronic Polyethyleneglycol3350 Use in Constipated Patients Completed NCT00164125 Phase 4 polyethyleneglycol3350
47 Extended Use of Polyethyleneglycol3350 Laxative in Constipated Patients Completed NCT00153153 Phase 4 polyethyleneglycol3350
48 Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation Completed NCT00149877 Phase 4 Tegaserod
49 A Multi-center, Open-labeled Study of the Safety, Efficacy, and Pharmacokinetics of Lubiprostone in Pediatric Patients With Constipation Completed NCT00452335 Phase 4 Lubiprostone;Lubiprostone;Lubiprostone
50 A Pilot Study of a New PEG3350 Dose Formulation For Use in Constipated Children Completed NCT00583609 Phase 4 PEG3350

Search NIH Clinical Center for Constipation

Cochrane evidence based reviews: constipation

Genetic Tests for Constipation

Genetic tests related to Constipation:

# Genetic test Affiliating Genes
1 Constipation 29

Anatomical Context for Constipation

MalaCards organs/tissues related to Constipation:

40
Colon, Breast, Testes, Lung, Spinal Cord, Prostate, Liver

Publications for Constipation

Articles related to Constipation:

(show top 50) (show all 23517)
# Title Authors PMID Year
1
Effectiveness of different acupuncture courses for functional constipation: A protocol for systematic review and network meta-analysis. 42 61
32481288 2020
2
Bacillus coagulans (PROBACI) in treating constipation-dominant functional bowel disorders. 61 42
32384482 2020
3
The effect of probiotics used as a single therapy on functional constipation: Study protocol for a systematic review and meta-analysis. 61 42
32332627 2020
4
Prostate preserving resection of a rare giant peri-prostatic solitary fibrous tumor. 61
32382508 2020
5
König's Syndrome After Roux-en-Y Gastric Bypass: Candy Cane Twist. 61
32377990 2020
6
The ketogenic diet for infants: How long can you go? 61
32422496 2020
7
Effect of an electronic medical record design modification on laxative co-prescribing among hospitalised patients taking opioids: A before-and-after study. 61
32473568 2020
8
Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study. 61
32442785 2020
9
Pediatric-Onset Postural Orthostatic Tachycardia Syndrome in a Single Tertiary Care Center. 61
32314650 2020
10
Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies. 61
30374191 2020
11
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer. 61
32286687 2020
12
The Patients with Hirschsprung's Disease Who Underwent Pull-Through at Age Less than 1 Year: Longitudinal Bowel Function. 61
32161985 2020
13
Morphine-induced respiratory depression is independent of β-arrestin2 signalling. 61
32052419 2020
14
Use of a Noninvasive Brain-Penetrating Peptide-Drug Conjugate Strategy to Improve the Delivery of Opioid Pain Relief Medications to the Brain. 61
32327529 2020
15
Systematic review with meta-analysis: efficacy and safety of treatments for opioid-induced constipation. 61
32462777 2020
16
Characteristics of Anorectal Malformations in Children at the United States-Mexico Border: A 3-Year Study. 61
32141997 2020
17
Nonsteroidal Anti-Inflammatory Drugs and Opioids in Postsurgical Dental Pain. 61
32286125 2020
18
Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin. 61
31732854 2020
19
Bowel preparation prior to minimally invasive sacrocolpopexy: a randomized controlled trial. 61
31773199 2020
20
Improved efficacy, tolerance, safety, and abuse liability profile of the combination of CR4056 and morphine over morphine alone in rodent models. 61
32154915 2020
21
TAS-303 Ameliorates Carbachol-Induced Detrusor Overactivity in Rats, Revealing Its Therapeutic Potential for Overactive Bladder. 61
32332112 2020
22
Complications with focus on delirium during hospital stay related to femoral nerve block compared to conventional pain management among patients with hip fracture - A randomised controlled trial. 61
32360090 2020
23
Use of over-the-counter laxatives by community-dwelling adults to treat and prevent constipation: a national cross-sectional study. 61
32296858 2020
24
Solitary Rectal Ulcer Syndrome in Children: A Report of 140 Cases. 61
32097373 2020
25
Bladder bowel dysfunction in children with Down's syndrome. 61
32458130 2020
26
Transcutaneous Neuromodulation at ST36 (Zusanli) is More Effective than Transcutaneous Tibial Nerve Stimulation in Treating Constipation. 61
30720579 2020
27
Young-Onset Ischemic Colitis: A Condition of Elusive Etiology Frequently Associated With Immune Dysregulation. 61
31870209 2020
28
A case of severe megacolon due to acquired isolated hypoganglionosis after low anterior resection for lower rectal cancer. 61
31828729 2020
29
Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study. 61
32487150 2020
30
Gastrointestinal motility evaluation in children with orthostatic intolerance: Mayo Clinic experience. 61
32483845 2020
31
Children with Functional Nausea-Comorbidities outside the Gastrointestinal Tract. 61
32532651 2020
32
Atopic dermatitis in the elderly Caucasian population: diagnostic clinical criteria and review of the literature. 61
32311089 2020
33
Two novel compound heterozygous mutations in NGLY1as a cause of congenital disorder of deglycosylation: a case presentation. 61
32576142 2020
34
Health-related quality-of-life after radical cystectomy among Norwegian men and women compared to the general population. 61
32343159 2020
35
High Patient Disease Burden in a Cross-Sectional, Multicenter Contact Registry Study of Eosinophilic Gastrointestinal Diseases. 61
32541201 2020
36
Clozapine in bipolar disorder: A systematic review and meta-analysis. 61
32182485 2020
37
Long-term outcomes of single-incision laparoscopic technique in Soave procedure compared with heart-shaped anastomosis for Hirschsprung disease. 61
32172319 2020
38
A 7-Year-Old Boy With Recurring Episodes of Abdominal Pain. 61
32544143 2020
39
Predicting Phenoconversion in Pure Autonomic Failure. 61
32546656 2020
40
Ileus caused by small bowel, ileocaecal and rectal endometriosis misdiagnosed as Crohn's disease and managed by synchronous ileocaecal and rectal resection. 61
32538117 2020
41
Comparison of Serum Vitamin D Levels in Relation to Bowel and Bladder Symptoms in Women with Vulvar Diseases. 61
30747611 2020
42
A prospective real-world analysis of erenumab in refractory chronic migraine. 61
32487102 2020
43
Safety and clinical effectiveness of Withania Somnifera (Linn.) Dunal root in human ailments. 61
32201301 2020
44
Randomised clinical trial: linaclotide vs placebo-a study of bi-directional gut and brain axis. 61
32406112 2020
45
Comparison of clinical and pathological findings of patients undergoing elective colectomy for uncomplicated diverticulitis. 61
32483125 2020
46
Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects. 61
32323104 2020
47
Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study. 61
32493206 2020
48
Impact of neurosurgical enhanced recovery after surgery (ERAS) program on health-related quality of life in glioma patients: a secondary analysis of a randomized controlled trial. 61
32506368 2020
49
Association between combinations of nutritional status and quality of life and food purchasing motives among the elderly in South Korea. 61
32546173 2020
50
Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy. 61
32492185 2020

Variations for Constipation

ClinVar genetic disease variations for Constipation:

6 (show all 12) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SIL1 NC_000005.10:g.139189727_139201554deldeletion Pathogenic 812923 5:138525416-138537243
2 RET NM_020975.6(RET):c.2753T>C (p.Met918Thr)SNV Pathogenic 13919 rs74799832 10:43617416-43617416 10:43121968-43121968
3 46;XX;t(7;13)(p13;q34)dnTranslocation Pathogenic 267841
4 46;XY;t(9;11)(q34;p11.2)dnTranslocation Pathogenic 267847
5 46;XX;t(19;21)(q13.3;q22.3)dnTranslocation Pathogenic 268035
6 EBF3 NM_001005463.3(EBF3):c.280_283del (p.Glu94fs)deletion Pathogenic 375502 rs1057519521 10:131761639-131761642 10:129963375-129963378
7 PPOX NM_001122764.3(PPOX):c.1353T>G (p.Tyr451Ter)SNV Pathogenic 523355 rs148292941 1:161140885-161140885 1:161171095-161171095
8 COL17A1 NM_000494.4(COL17A1):c.4143_4144AG[1] (p.Glu1382fs)short repeat Pathogenic 599000 rs765243124 10:105793711-105793714 10:104033953-104033956
9 46;X;t(Y;16)(q11.23;p11.2);t(6;21)(p21.3;p13)dnTranslocation Likely pathogenic 267834
10 MT-TP , MT-TT m.15923A>GSNV Conflicting interpretations of pathogenicity 39575 rs1556424691 MT:15923-15923 MT:15923-15923
11 ARID1B NM_020732.3(ARID1B):c.4110G>A (p.Pro1370=)SNV Conflicting interpretations of pathogenicity 210291 rs797045277 6:157520041-157520041 6:157198907-157198907
12 LSM1 NM_014462.3(LSM1):c.231+4A>CSNV Uncertain significance 623485 rs775468919 8:38027316-38027316 8:38169798-38169798

Expression for Constipation

Search GEO for disease gene expression data for Constipation.

Pathways for Constipation

GO Terms for Constipation

Cellular components related to Constipation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.96 VIP TAC1 SST PYY MLN GDNF
2 integral component of plasma membrane GO:0005887 9.92 SLC6A4 RET OPRM1 KIT HTR4 HTR3A
3 neuron projection GO:0043005 9.85 VIP SLC6A4 OPRM1 HTR3A CALCA
4 extracellular space GO:0005615 9.81 TAC1 SST SIL1 PYY KIT GDNF
5 perikaryon GO:0043204 9.67 VIP OPRM1 FLNA CCK
6 integral component of presynaptic membrane GO:0099056 9.61 SLC6A4 OPRM1 HTR3A
7 integral component of postsynaptic membrane GO:0099055 9.58 SLC6A4 OPRM1 HTR3A
8 axon GO:0030424 9.43 TAC1 RET OPRM1 HTR3A CCK CALCA
9 neuronal cell body GO:0043025 9.17 TAC1 SST RET HTR3A FLNA CCK

Biological processes related to Constipation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.01 VIP RET OPRM1 KIT HTR4 HTR3A
2 response to drug GO:0042493 9.73 SST SLC6A4 RET PPOX
3 chemical synaptic transmission GO:0007268 9.62 TAC1 SST HTR4 HTR3A
4 neuropeptide signaling pathway GO:0007218 9.46 TAC1 PYY OPRM1 CALCA
5 regulation of sensory perception of pain GO:0051930 9.43 VIP OPRM1 CCK
6 enteric nervous system development GO:0048484 9.37 RET GDNF
7 G protein-coupled receptor signaling pathway GO:0007186 9.28 VIP TAC1 SST PYY OPRM1 MLN
8 response to pain GO:0048265 9.13 TAC1 RET CALCA

Molecular functions related to Constipation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.33 VIP PYY CCK
2 peptide hormone receptor binding GO:0051428 9.26 VIP CCK
3 serotonin binding GO:0051378 9.13 SLC6A4 HTR4 HTR3A
4 hormone activity GO:0005179 9.1 VIP SST PYY MLN CCK CALCA

Sources for Constipation

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....